Beneficial effects of bile acid receptor agonists in pulmonary disease models

References

• Hofmann AF, Hagey LR, Krasowski MD. Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res. 2010;51(2):226–246.
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014;66:948–983.
   PubMed Web of Science ®Google Scholar
• Copple BL, Li T. Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res. 2016;104:9–21.
   PubMed Web of Science ®Google Scholar
• Marin JJ, Macias RI, Briz O, et al. Bile acids in physiology, pathology and pharmacology. Curr Drug Metab. 2016;17(1):4–29.
   Web of Science ®Google Scholar
• Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147–191.
   PubMed Web of Science ®Google Scholar
• Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284:1362–1365.
   PubMed Web of Science ®Google Scholar
• Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science. 1999;284:1365–1368.
   PubMed Web of Science ®Google Scholar
• Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov. 2008;7(8):678–693.
   PubMed Web of Science ®Google Scholar
• Schaap FG, Trauner M, Jansen PL. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11(1):55–67.
   PubMed Web of Science ®Google Scholar
• Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956–965.
   PubMed Web of Science ®Google Scholar
• Vaquero J, Briz O, Herraez E, et al. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim Biophys Acta. 2013;1833(10):2212–2219.
   PubMed Web of Science ®Google Scholar
• Houten SM, Volle DH, Cummins CL, et al. In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol Endocrinol. 2007;21(6):1312–1323.
   PubMedGoogle Scholar
• Higashiyama H, Kinoshita M, Asano S. Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray. Acta Histochem. 2008;110:86–93.
   PubMed Web of Science ®Google Scholar
• Popescu IR, Helleboid-Chapman A, Lucas A, et al. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity. FEBS Lett. 2010;584:2845–2851.
   PubMed Web of Science ®Google Scholar
• Cariou B, Van Harmelen K, Duran-Sandoval D, et al. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem. 2006;281:11039–11049.
   PubMed Web of Science ®Google Scholar
• Schote AB, Turner JD, Schiltz J, et al. Nuclear receptors in human immune cells: expression and correlations. Mol Immunol. 2007;44:1436–1445.
   PubMed Web of Science ®Google Scholar
• Ye L, Jiang Y, Zuo X. Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure. Biochem Biophys Res Commun. 2015;467:164–170.
   PubMed Web of Science ®Google Scholar
• Comeglio P, Filippi S, Sarchielli E, et al. Anti-fibrotic effects of chronic treatment with the selective fxr agonist obeticholic acid in the bleomycin-induced rat model of pulmonary fibrosis. J Steroid Biochem Mol Biol. 2017;168:26–37.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kast-Woelbern HR, Edwards PA. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J Biol Chem. 2003;278(1):104–110.
   PubMed Web of Science ®Google Scholar
• Vaquero J, Monte MJ, Dominguez M, et al. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochem Pharmacol. 2013;86(7):926–939.
   PubMed Web of Science ®Google Scholar
• Shaik FB, Prasad DV, Narala VR. Role of farnesoid X receptor in inflammation and resolution. Inflamm Res. 2015;64(1):9–20.
   PubMed Web of Science ®Google Scholar
• Han CY, Kim TH, Koo JH, et al. Farnesoid X receptor as a regulator of fuel consumption and mitochondrial function. Arch Pharm Res. 2016;39(8):1062–1074.
   PubMed Web of Science ®Google Scholar
• Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear receptors fxr, shp-1, and lrh-1 represses bile acid biosynthesis. Mol Cell. 2000;6:517–526.
   PubMed Web of Science ®Google Scholar
• Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem. 2001;276:28857–28865.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhao A, Lew J-L, et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem. 2003;278(51):51085–51090.
   PubMed Web of Science ®Google Scholar
• Katafuchi T, Esterhazy D, Lemoff A, et al. Detection of fgf15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry. Cell Metab. 2015;21:898–904.
   PubMed Web of Science ®Google Scholar
• Lee H, Zhang Y, Lee FY, et al. FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine. J Lipid Res. 2006;47:201–214.
   PubMed Web of Science ®Google Scholar
• Maneschi E, Vignozzi L, Morelli A, et al. FXR activation normalizes insulin sensitivity in visceral preadipocytes of a rabbit model of MetS. J Endocrinol. 2013;218:215–231.
   PubMed Web of Science ®Google Scholar
• Stayrook KR, Bramlett KS, Savkur RS, et al. Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology. 2005;146:984–991.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.
   PubMed Web of Science ®Google Scholar
• Wang XX, Jiang T, Shen Y, et al. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes. 2010;59:2916–2927.
   PubMed Web of Science ®Google Scholar
• Zhou B, Feng B, Qin Z, et al. Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy. Mol Cell Endocrinol. 2016;419:72–82.
   PubMed Web of Science ®Google Scholar
• Hendrick SM, Mroz MS, Greene CM, et al. Bile acids stimulate chloride secretion through CFTR and calcium-activated Cl- channels in Calu-3 airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2014;307(5):L407–418.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li T, Yu D, et al. FXR protects lung from lipopolysaccharide-induced acute injury. Mol Endocrinol. 2012;26:27–36.
   PubMedGoogle Scholar
• Chen B, Cai H-R, Xue S, et al. Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways. Respirology. 2016;21(6):1075–1080.
   PubMed Web of Science ®Google Scholar
• Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA. 2004;101:3668–3673.
   PubMed Web of Science ®Google Scholar
• He F, Li J, Mu Y, et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res. 2006;98:192–199.
   PubMed Web of Science ®Google Scholar
• Li J, Wilson A, Kuruba R, et al. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc Res. 2008;77:169–177.
   PubMed Web of Science ®Google Scholar
• Khurana S, Raufman J-P, Pallone TL. Bile acids regulate cardiovascular function. Clin Transl Sci. 2011;4:210–218.
   PubMed Web of Science ®Google Scholar
• Zollner G, Marschall H-U, Wagner M, et al. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm. 2006;3:231–251.
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang J, Liu Q, et al. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380–388.
   PubMed Web of Science ®Google Scholar
• Porez G, Prawitt J, Gross B, et al. Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res. 2012;53:1723–1737.
   PubMed Web of Science ®Google Scholar
• Gadaleta RM, Van Erpecum KJ, Oldenburg B, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut. 2011;60:463–472.
   PubMed Web of Science ®Google Scholar
• Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278:9435–9440.
   PubMed Web of Science ®Google Scholar
• Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology. 2009;50:861–870.
   PubMed Web of Science ®Google Scholar
• Keitel V, Görg B, Bidmon HJ, et al. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia. 2010;58(15):1794–1805.
   PubMed Web of Science ®Google Scholar
• Keitel V, Reinehr R, Gatsios P, et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. Hepatology. 2007;45:695–704.
   PubMed Web of Science ®Google Scholar
• Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun. 2008;372:78–84.
   PubMed Web of Science ®Google Scholar
• Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 2009;10(3):167–177.
   PubMed Web of Science ®Google Scholar
• Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011;14(6):747–757.
   PubMed Web of Science ®Google Scholar
• Wang Y-D, Chen W-D, Yu D, et al. The G‑protein‑coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology. 2011;54:1421–1432.
   PubMed Web of Science ®Google Scholar
• Zhou C, Shi Y, Li J, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak Phar Sci. 2013;26:761–765.
   PubMed Web of Science ®Google Scholar
• Han S, Chiang JY. Mechanism of vitamin D receptor inhibition of cholesterol 7α-hydroxylase gene transcription in human hepatocytes. Drug Metab Dispos. 2009;37:469–478.
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Goodwin B, Jones SA, et al. The nuclear receptor pxr is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA. 2001;98:3369–3374.
   PubMed Web of Science ®Google Scholar
• Kruse MS, Suarez LG, Coirini H. Regulation of the expression of LXR in rat hypothalamic and hippocampal explants. Neurosci Lett. 2017;639:53–58.
   PubMed Web of Science ®Google Scholar
• Schmidt DR, Holmstrom SR, Fon Tacer K, et al. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J Biol Chem. 2010;285:14486–14494.
   PubMed Web of Science ®Google Scholar
• Huhtakangas JA, Olivera CJ, Bishop JE, et al. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1α,25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol. 2004;18:2660–2671.
   PubMed Web of Science ®Google Scholar
• Schedel M, Jia Y, Michel S, et al. 1,25D3 prevents CD8(+)Tc2 skewing and asthma development through VDR binding changes to the Cyp11a1 promoter. Nat Commun. 2016;7:10213.
   PubMed Web of Science ®Google Scholar
• Shi -Y-Y, Liu T-J, Fu J-H, et al. Vitamin D/VDR signaling attenuates lipopolysaccharide‑induced acute lung injury by maintaining the integrity of the pulmonary epithelial barrier. Mol Med Rep. 2016;13(2):1186–1194.
   PubMed Web of Science ®Google Scholar
• Kliewer SA. Nuclear receptor pxr: discovery of a pharmaceutical anti-target. J Clin Invest. 2015;125:1388–1389.
   PubMed Web of Science ®Google Scholar
• Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A. 1998;95:12208–12213.
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 α-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol. 2005;288:G74–G84.
   PubMed Web of Science ®Google Scholar
• Studer E, Zhou X, Zhao R, et al. Conjugated bile acids activate the sphingosine-1- phosphate receptor 2 in primary rodent hepatocytes. Hepatology. 2012;55:267–276.
   PubMed Web of Science ®Google Scholar
• Gupta S, Stravitz RT, Dent P, et al. Down-regulation of cholesterol 7alpha-hydroxylase (cyp7a1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-jun n-terminal kinase pathway. J Biol Chem. 2001;276:15816–15822.
   PubMed Web of Science ®Google Scholar
• Zhou H, Hylemon PB. Bile acids are nutrient signaling hormones. Steroids. 2014;86:62–68.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45:3569–3572.
   PubMed Web of Science ®Google Scholar
• Rizzo G, Passeri D, De Franco F, et al. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol. 2010;78:617–630.
   PubMed Web of Science ®Google Scholar
• Roda A, Pellicciari R, Gioiello A, et al. Semisynthetic bile acid FXR and TGR5 agonists: physicochemical properties, pharmacokinetics, and metabolism in the rat. J Pharmacol Exp Ther. 2014;350(1):56–68.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015;148(4):751–761.
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145:574–582.
   PubMed Web of Science ®Google Scholar
• Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631–643.
   PubMed Web of Science ®Google Scholar
• Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs. 2016;76(12):1221–1226.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Filippi S, Comeglio P, et al. Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit. Mol Cell Endocrinol. 2014;384(1–2):143–154.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Morelli A, Filippi S, et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med. 2011;8(1):57–77.
   PubMed Web of Science ®Google Scholar
• Li YT, Swales KE, Thomas GJ, et al. Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol. 2007;27:2606–2611.
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Guignabert C, Humbert M, et al. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res. 2014;115:165–175.
   PubMed Web of Science ®Google Scholar
• Guazzi M, Phillips SA, Arena R, et al. Endothelial dysfunction and lung capillary injury in cardiovascular diseases. Prog Cardiovasc Dis. 2015;57:454–462.
   PubMed Web of Science ®Google Scholar
• Lang M, Kojonazarov B, Tian X, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One. 2012;7:e43433.
   PubMed Web of Science ®Google Scholar
• Ataya A, Cope J, Alnuaimat H. A review of targeted pulmonary arterial hypertension-specific pharmacotherapy. J Clin Med. 2016;5(12):E114.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 2003;124:247–254.
   PubMed Web of Science ®Google Scholar
• Kitterman N, Poms A, Miller DP, et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc. 2012;87:825–834.
   PubMed Web of Science ®Google Scholar
• Benza RL, Tapson VF, Gomberg-Maitland M, et al. One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant. 2013;32:889–896.
   PubMed Web of Science ®Google Scholar
• Jing Z-C, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127:624–633.
   PubMed Web of Science ®Google Scholar
• Olschewski H, Hoeper MM, Behr J, et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir Med. 2010;104(5):731–740.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–2533.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55:1915–1922.
   PubMed Web of Science ®Google Scholar
• Waxman AB, Zamanian RT. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Am J Cardiol. 2013;111(S5):1A–16A.
   PubMed Web of Science ®Google Scholar
• Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010–3019.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.
   PubMed Web of Science ®Google Scholar
• Corbin JD, Beasley A, Blount MA, et al. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun. 2005;334:930–938.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–340.
   PubMed Web of Science ®Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157.
   PubMed Web of Science ®Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894–2903.
   PubMed Web of Science ®Google Scholar
• Arif SA, Poon H. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther. 2011;33:993–1004.
   PubMed Web of Science ®Google Scholar
• Sitbon O, Sattler C, Bertoletti L, et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016;47:1727–1736.
   PubMed Web of Science ®Google Scholar
• Stenmark KR, Meyrick B, Galie N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol. 2009;297:L1013–L1032.
   PubMed Web of Science ®Google Scholar
• Sakuma F, Miyata M, Kasukawa R. Suppressive effect of prostaglandin E1 on pulmonary hypertension induced bymonocrotaline in rats. Lung. 1999;177:77–88.
   PubMed Web of Science ®Google Scholar
• Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698–702.
   PubMed Web of Science ®Google Scholar
• Shaik FB, Panati K, Narasimha VR, et al. Chenodeoxycholic acid attenuates ovalbumin-induced airway inflammation in murine model of asthma by inhibiting the T(H)2 cytokines. Biochem Biophys Res Commun. 2015;463(4):600–605.
   PubMed Web of Science ®Google Scholar
• Willart MA, Van Nimwegen M, Grefhorst A, et al. Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy. 2012;67(12):1501–1510.
   PubMed Web of Science ®Google Scholar
• Vignozzi L, Morelli A, Cellai I, et al. Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension. J Steroid Biochem Mol Biol. 2017;165(PtB):277–292.
   PubMed Web of Science ®Google Scholar
• Yen C-H, Leu S, Lin Y-C, et al. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. J Cardiovasc Pharmacol. 2010;55:574–584.
   PubMed Web of Science ®Google Scholar
• Schroll S, Sebah D, Wagner M, et al. Improvement of exercise capacity in monocrotaline-induced pulmonary hypertension by the phosphodiesterase-5 inhibitor Vardenafil. Respir Physiol Neurobiol. 2013;186:61–64.
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Phan SH, Imaizumi K, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2010;43:161–172.
   PubMed Web of Science ®Google Scholar
• Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA. 2006;103:13180–13185.
   PubMed Web of Science ®Google Scholar
• Díez M, Musri MM, Ferrer E, et al. Endothelial progenitor cells undergo an endothelial-to-mesenchymal transition-like process mediated by TGFbetaRI. Cardiovasc Res. 2010;88:502–511.
   PubMed Web of Science ®Google Scholar
• Arcot SS, Lipke DW, Gillespie MN, et al. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol. 1993;46:1086–1091.
   PubMed Web of Science ®Google Scholar
• Lu A, Zuo C, He Y, et al. EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. J Clin Invest. 2015;125:1228–1242.
   PubMed Web of Science ®Google Scholar
• Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol. 1994;144:286–295.
   PubMed Web of Science ®Google Scholar
• Long L, Crosby A, Yang X, et al. Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation. 2009;119:566–576.
   PubMed Web of Science ®Google Scholar
• Courboulin A, Tremblay VL, Barrier M, et al. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res. 2011;12:128.
   PubMedGoogle Scholar
• Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104:236–244.
   PubMed Web of Science ®Google Scholar
• Golembeski SM, West J, Tada Y, et al. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest. 2005;128(6 Suppl):572S–573S.
   PubMed Web of Science ®Google Scholar
• Savale L, Tu L, Rideau D, et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6.
   PubMed Web of Science ®Google Scholar
• Cracowski J-L, Chabot F, Labarère J, et al. Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension. Eur Respir J. 2014;43:915–917.
   PubMed Web of Science ®Google Scholar
• Shatanawi A, Romero MJ, Iddings JA, et al. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol. 2011;300:C1181–1192.
   PubMed Web of Science ®Google Scholar
• Yamazato Y, Ferreira AJ, Hong K-H, et al. Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension. 2009;54:365–371.
   PubMed Web of Science ®Google Scholar
• Li G, Liu Y, Zhu Y, et al. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung. 2013;191:327–336.
   PubMed Web of Science ®Google Scholar
• Dai H, Gong Y, Xiao Z, et al. Decreased levels of serum Angiotensin-(1-7) in patients with pulmonary arterial hypertension due to congenital heart disease. Int J Cardiol. 2014;176:1399–1401.
   PubMed Web of Science ®Google Scholar
• Shenoy V, Kwon KC, Rathinasabapathy A, et al. Oral delivery of Angiotensin-converting enzyme 2 and Angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension. 2014;64:1248–1259.
   PubMed Web of Science ®Google Scholar
• Dai H, Jiang L, Xiao Z, et al. ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12:374.
   PubMed Web of Science ®Google Scholar
• Ranchoux B, Antigny F, Rucker-Martin C, et al. Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation. 2015;131:1006–1018.
   PubMed Web of Science ®Google Scholar
• Du L, Sullivan CC, Chu D, et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 2003;348:500–509.
   PubMed Web of Science ®Google Scholar
• Yang J, Li X, Al-Lamki RS, et al. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ Res. 2010;107:252–262.
   PubMed Web of Science ®Google Scholar
• Sawada H, Saito T, Nickel NP, et al. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. J Exp Med. 2014;211:263–280.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–1961.
   PubMed Web of Science ®Google Scholar
• Sgalla G, Biffi A, Richeldi L. Idiopathic pulmonary fibrosis: diagnosis, epidemiology and natural history. Respirology. 2016;21:427–437.
   PubMed Web of Science ®Google Scholar
• Phan SH. The myofibroblast in pulmonary fibrosis. Chest. 2002;122:286S–289S.
   PubMed Web of Science ®Google Scholar
• Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol. 2005;166:1321–1332.
   PubMed Web of Science ®Google Scholar
• Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002;62:1613–1618.
   PubMed Web of Science ®Google Scholar
• Bolós V, Peinado H, Pérez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116:499–511.
   PubMed Web of Science ®Google Scholar
• Betensley A, Sharif R, Karamichos D. A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis. J Clin Med. 2016;6(1):E2.
   PubMed Web of Science ®Google Scholar
• Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. J Intern Med. 2017;281(2):149–166.
   PubMed Web of Science ®Google Scholar
• Myllärniemi MKR, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib and N-acetylcysteine. Eur Clin Resp J. 2015;2:1–10.
   Web of Science ®Google Scholar
• Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–133.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebocontrolled trial. Lancet. 2009;374:222–228.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75–81.
   PubMed Web of Science ®Google Scholar
• Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42:1622–1632.
   PubMed Web of Science ®Google Scholar
• Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131:897–899.
   PubMed Web of Science ®Google Scholar
• Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest. 2013;143:1699–1708.
   PubMed Web of Science ®Google Scholar
• Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1:369–376.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4:381–389.
   PubMed Web of Science ®Google Scholar
• Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88–95.
   PubMed Web of Science ®Google Scholar
• Juarez MM, Chan AL, Norris AG, et al. Acute exacerbation of idiopathic pulmonary fibrosis - a review of current and novel pharmacotherapies. J Thorac Dis. 2015;7:499–519.
   PubMed Web of Science ®Google Scholar
• Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med. 2015;191:252–254.
   PubMed Web of Science ®Google Scholar
• Spagnolo P, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy. Pharmacol Ther. 2015;152:18–27.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–19.
   PubMed Web of Science ®Google Scholar
• Carlos WG, Strek ME, Wang TS, et al. Treatment of idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2016;13:115–117.
   PubMed Web of Science ®Google Scholar
• Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev. 2011;20:85–97.
   PubMedGoogle Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Bonella F, Wijsenbeek M, et al. Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives. BioMed Res Int. 2015;2015:329481.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–1769.
   PubMed Web of Science ®Google Scholar
• King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–2092.
   PubMed Web of Science ®Google Scholar
• Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40:362–382.
   PubMed Web of Science ®Google Scholar
• Della Latta V, Cecchettini A, Del Ry S, et al. Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res. 2015;97:122–130.
   PubMed Web of Science ®Google Scholar
• Hoshino T, Okamoto M, Sakazaki Y, et al. Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice. Am J Respir Cell Mol Biol. 2009;41(6):661–670.
   PubMed Web of Science ®Google Scholar
• Kasai H, Allen JT, Mason RM, et al. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res. 2005;6:56.
   PubMed Web of Science ®Google Scholar
• Xu G-P, Li Q-Q, Cao X-X, et al. The effect of TGF-β1 and Smad7 gene transfer on the phenotypic changes of rat alveolar epithelial cells. Cell Mol Biol Lett. 2007;12:457–472.
   PubMed Web of Science ®Google Scholar
• Jayachandran A, Königshoff M, Yu H, et al. SNAI transcription factors mediate epithelial–mesenchymal transition in lung fibrosis. Thorax. 2009;64:1053–1061.
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163–176.
   PubMed Web of Science ®Google Scholar
• Fielding CA, Jones GW, McLoughlin RM, et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity. 2014;40:40–50.
   PubMed Web of Science ®Google Scholar
• Takizawa H, Satoh M, Okazaki H, et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol. 1997;107:175–181.
   PubMed Web of Science ®Google Scholar
• Aumiller V, Balsara N, Wilhelm J, et al. WNT/β-catenin signaling induces IL-1β expression by alveolar epithelial cells in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2013;49:96–104.
   PubMed Web of Science ®Google Scholar
• O’Donoghue RJ, Knight DA, Richards CD, et al. Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med. 2012;4:939–951.
   PubMed Web of Science ®Google Scholar
• Wilson MS, Madala SK, Ramalingam TR, et al. Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent. J Exp Med. 2010;207:535–552.
   PubMed Web of Science ®Google Scholar
• Pardo A, Cabrera S, Maldonado M, et al. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016;17:23.
   PubMed Web of Science ®Google Scholar
• McMahan RH, Wang XX, Cheng LL, et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem. 2013;288:11761–11770.
   PubMed Web of Science ®Google Scholar
• Guo C, Xie S, Chi Z, et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity. 2016;45(4):802–816.
   PubMed Web of Science ®Google Scholar
• Pellicciari R, Gioiello A, Macchiarulo A, et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem. 2009;52:7958–7961.
   PubMed Web of Science ®Google Scholar
• Miyazaki-Anzai S, Masuda M, Levi M, et al. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis. PLoS One. 2014;9(9):e108270.
   PubMed Web of Science ®Google Scholar